Close

Gabelli Starts bluebird bio (BLUE) at Buy (Earlier)

July 12, 2018 9:58 AM EDT
Get Alerts BLUE Hot Sheet
Price: $1.37 --0%

Rating Summary:
    13 Buy, 16 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 7 | Down: 3 | New: 1
Join SI Premium – FREE

Gabelli initiates coverage on bluebird bio (NASDAQ: BLUE) with a Buy rating and a price target of $239.00.

Analyst Jing He is positive on bb2121. They estimate the BCMA CAR-T market to be $3.9bn in MM in 2023 and bb2121/bb21217 will obtain 45% market share. They expect the therapy to reach peak sales of $3.0bn in 2027. bluebird is entitled to 50% of US commercial rights and ~10% ex-US royalties.

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $178.35 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage